Overview

Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome

Status:
Recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
This is a pilot, open-label Phase 2, single-center, repeat dose, single cohort, proof-of-concept, safety, pharmacodynamics and efficacy study of dapansutrile capsules to be conducted in subjects with Schnitzler's syndrome (SchS) currently well controlled by anakinra therapy. At least 5 but no more than 10 subjects will be enrolled.
Phase:
Phase 2
Details
Lead Sponsor:
Olatec Therapeutics LLC
Collaborator:
Radboud University
Treatments:
Dapansutrile